Single-Dose MM120 (Lysergide) Shows Promise in Treating Generalized Anxiety Disorder: Phase 2b RCT Results

Highlight

This randomized controlled trial (RCT) evaluated the efficacy and safety of MM120 (lysergide D-tartrate) as a single-dose treatment for moderate to severe generalized anxiety disorder (GAD). A dose-response relationship was established, with 100 µg and 200 µg doses producing statistically significant and clinically meaningful reductions in anxiety severity versus placebo at 4 weeks. Adverse events were dose-dependent and consistent with known pharmacological effects of MM120, primarily visual perceptual changes and nausea.

Study Background